NCT00837785View on ClinicalTrials.gov

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

BG00012

240 mg (two 120 mg capsules) orally three times a day

DRUG

BG00012

240 mg (two 120 mg capsules) orally twice a day

Trial Locations (1)

Unknown

Research Site, Berlin

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00837785 - A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS | Biotech Hunter | Biotech Hunter